Search Results - "Ziemssen, F"

Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials by Ziemssen, F, Feltgen, N, Holz, F G, Guthoff, R, Ringwald, A, Bertelmann, T, Wiedon, A, Korb, C

“…While randomized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional…”
Get full text

Conjunctival amyloidosis — clinical and histopathologic features by Suesskind, D., Ziemssen, F., Rohrbach, J. M.

“…Purpose Conjunctival amyloidosis is a rare disorder. It is often clinically not suspected or diagnosed. This study intended to demonstrate the clinical and…”
Get full text

Human Platelets Take up Anti-VEGF Agents by Sobolewska, B., Fehrenbacher, B., Münzer, P., Kalbacher, H., Geue, S., Stellos, Konstantinos, Schaller, M., Ziemssen, F.

“…Purpose. Growing evidence suggests different systemic exposure of anti-vascular endothelial growth factor (anti-VEGF) agents with repeated intravitreal…”
Get full text

Influence of aflibercept on platelet activation profile by Sobolewska, B., Golenko, J., Poeschel, S., Grimmel, C., Gatsiou, A., Sopova, K., Biedermann, T., Schenke-Layland, K., Stellos, K., Ziemssen, F.

“…Aflibercept appears to accumulate in systemic circulation following intravitreal injections in therapy of neovascular age-related macular degeneration. This…”
Get full text

Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation by R. Veelken, S. Ebel, A. Schindler, F. Lordick, M.F. Struck, C. Girbardt, F. Ziemssen, D. Seehofer, T. Denecke, T. Berg, F. van Bömmel

“…Background: Hepatic chemosaturation by isolated percutaneous liver perfusion (CS-PHP) with melphalan controls hepatic tumor growth. However, optimal treatment…”
Get full text

Establishment of a retinal hypoxia organ culture model by Schnichels, S, Blak, M, Hurst, J, Dorfi, T, Bartz-Schmidt, K U, Ziemssen, F, Spitzer, M S, Schultheiss, M

“…Hypoxia plays an important role in several retinal diseases, especially in central retinal artery occlusion (CRAO). Although CRAO has been known for over a…”
Get full text

Regional Differences in the Care of Patients with Neovascular Age-Related Macular Degeneration, Based on the Non-Interventional OCEAN Study by Ziemssen, F, Hufenbach, U, Wiedon, A, Scheffler, M, Bertelmann, T

“…The main cause of blindness in the elderly in Germany is neovascular age-related macular degeneration (nAMD). In the non-interventional OCEAN study, data were…”
Get more information

Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography study by Leitritz, M, Gelisken, F, Inhoffen, W, Voelker, M, Ziemssen, F

“…Background  Retinal pigment epithelium (RPE) tears after bevacizumab treatment for neovascular age-related macular degeneration accompanied by a pigment…”
Get full text

Prospective noninterventional BLUE SKY study evaluating the efficacy of brolucizumab in treatment-naïve and previously treated patients with neovascular AMD by Faatz, H, Feltgen, N, Gutfleisch, M, Heimes-Bussmann, B, Krohne, T U, Liakopoulos, S, Liegl, R, Lommatzsch, A, Mussinghoff, P, Rehak, M, Schmitz-Valckenberg, S, Spital, G, Stanzel, B, Ziemssen, F, Hägele, B, Junkes, C, Porstner, M, Vögeler, J, Gmeiner, B, Pauleikhoff, D

“…Intravitreal injection of anti-vascular endothelial growth factor (VEGF) is the standard treatment for patients with neovascular age-related macular…”
Get more information

Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration by Gelisken, F, Ziemssen, F, Voelker, M, Bartz-Schmidt, K U, Inhoffen, W

“…Purpose To analyse retinal pigment epithelial (RPE) tears following single administration of intravitreal bevacizumab for neovascular age-related macular…”
Get full text

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration by Aisenbrey, S, Ziemssen, F, Völker, M, Gelisken, F, Szurman, P, Jaissle, G, Grisanti, S, Bartz-Schmidt, K U

“…The purpose of the study is to report data on short-term safety of intravitreal bevacizumab treatment and its effect on visual function, central retinal…”
Get full text

Research funding in German ophthalmology by Ziemssen, F, Meltendorf, C

“…Since 2004 applications for research funding in ophthalmology have been evaluated together with those from neurosurgery, neuropathology, psychiatry,…”
Get more information

Efficacy for remyelination and safety of anti-lingo-1 monoclonal antibody (biib033) in acute optic neuritis: results from the renew study by Kurukulasuriya, N, Fernandez, O, Balcer, L, Galetta, S, Aktas, O, Ziemssen, T, Vanopdenbosch, L, Butzkueven, H, Ziemssen, F, Massacesi, L, Chai, Y, Xu, L, Freeman, S, Cadavid, D

Get full text

Myopic CNV by Voykov, B, Ziemssen, F

“…Choroidal neovascularisation secondary to pathological myopia is the most common cause of severe visual impairment in myopic patients younger than 50 years…”
Get more information

Chronic central serous chorioretinopathy (cCSC): differential diagnosis to choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) by Inhoffen, W, Ziemssen, F, Bartz-Schmidt, K U

“…Central neurosensory detachments (NSD) with time-dependent height constitute a disease called central serous chorioretinopathy (CSC), if not arising from…”
Get more information

Effects of bevacizumab on retinal function in isolated vertebrate retina by Lüke, M, Warga, M, Ziemssen, F, Gelisken, F, Grisanti, S, Schneider, T, Lüke, C, Partsch, M, Bartz-Schmidt, K U, Szurman, P

“…Background: Bevacizumab (Avastin) is a recombinant protein that targets vascular endothelial growth factor (VEGF). In vitro, bevacizumab inhibits VEGF induced…”
Get full text

Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells by Peters, Swaantje, Julien, Sylvie, Heiduschka, Peter, Grisanti, Salvatore, Ziemssen, Focke, Adler, Martin, Schraermeyer, Ulrich, Bartz-Schmidt, Karl-Ulrich

“…Background: Bevacizumab is an antiangiogenic compound developed to target tumour vessels. Its off-label use in ophthalmology requires in vitro testing on…”
Get full text

Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy by Ziemssen, F, Voelker, M, Inhoffen, W, Bartz-Schmidt, K U, Gelisken, F

Get full text

A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation by VORGERD, M, RICKER, K, ZIEMSSEN, F, KRESS, W, GOEBEL, H. H, NIX, W. A, KUBISCH, C, SCHOSER, B. G. H, MORTIER, W

“…To determine the cause of sporadic rippling muscle disease (RMD) in a 24-year-old patient. RMD is a rare myopathy characterized by percussion-induced rapid…”
Get full text

The International Intravitreal Bevacizumab Safety Survey by Ziemssen, F, Grisanti, S, Bartz-Schmidt, K U

“…When using a product for an indication not in the approved label, doctors have the responsibility to be well informed about the product and its potential…”
Get full text